Results 141 to 150 of about 517,948 (338)
Nature CommunicationsThrombopoietin (Tpo) is the primary regulator of megakaryocyte and platelet numbers and is required for haematopoetic stem cell maintenance. Tpo functions by binding its receptor (TpoR, a homodimeric Class I cytokine receptor) and initiating cell ...
Kaiseal T. G. Sarson-Lawrence +13 more
doaj +1 more source
CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1 [PDF]
, 1998 Sarah Flynn +4 more
openalex +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple ...
Shu Yang +9 more
wiley +1 more source
PD-1 signaling negatively regulates the common cytokine receptor γ chain via MARCH5-mediated ubiquitination and degradation to suppress anti-tumor immunity. [PDF]
Cell Res, 2023 Liu R +6 more
europepmc +1 more source
CSF Tau Is a Biomarker of Hippocampal Injury in Cryptogenic New‐Onset Refractory Status Epilepticus
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Cryptogenic new‐onset refractory status epilepticus (cNORSE) is a devastating condition characterized by the de novo onset of status epilepticus with unclear etiology. The identification of relevant early biomarkers in cNORSE is important to elucidate pathophysiology, aid clinical decision‐making, and prognosticate outcomes in cNORSE.
Yihui Goh +8 more
wiley +1 more source
Neural activities of IL‐6‐type cytokines often depend on soluble cytokine receptors [PDF]
, 1999 Pia März, U. Otten, Stefan Rose‐John
openalex +1 more source
Arthritis Care &Research, EarlyView.Objective This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods In an open‐label, phase 1 study (SELECT‐YOUTH), enrolled patients, aged 2 to <18 years with pcJIA, received body weight–based ...
Hermine I. Brunner +12 more
wiley +1 more source
Sequential control of myeloid cell proliferation and differentiation by cytokine receptor-based chimeric antigen receptors. [PDF]
PLoS One, 2022 Nakajima K +4 more
europepmc +1 more source